A phase III, multicentre, randomised, placebo-controlled, double-blind study of atezolizumab (anti- PD-L1 antibody) as adjuvant therapy in patients with PD-L1 selected renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy